Symbols

TOI

The Oncology·NASDAQ

--(--)

Signals Analysis

Bullish signal 3

Bearish signal 2

Consensus Rating "Strong Buy"

MACD Death Cross

Ample Liquidity

EPS Beats Expectation

Revenue Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About TOI

The Oncology Institute, Inc.

A biotechnology company that develops and commercializes innovative cancer therapies and diagnostics

Industry

Healthcare Providers and Services

Established Date

11/01/2019

Listing Date

06/04/2020

Exchange

NASDAQ Stock Exchange

Full-time Employees

641

Fiscal Year Ends

12-31

Website

www.theoncologyinstitute.com

Security Type

Common stock

Office address

18000 Studebaker Rd, Suite 800, Cerritos, California 90703

Business

Introduction

The Oncology Institute, Inc., a Delaware corporation incorporated on November 1, 2019. The company is a leading value-based oncology company that manages community-based oncology practices serving patients in 76 clinics in 15 markets and 5 states in the United States. The company's community-based oncology clinics are staffed with 112 oncologists and advanced clinic providers. Of these clinics, 62 clinics are staffed with 101 medical personnel who are employed by their affiliated doctor-owned professional companies called "TOI PCs. ". The clinics managed by the company provide a range of oncology medical services, including physician services, in-house infusion and pharmacy, clinical trial services, radiology, innovative programs such as outpatient blood product transfusion, and round-the-clock patient support.

Company Financials

EPS

TOI has released its 2025 Q4 earnings. EPS was reported at -0.06, versus the expected -0.09, beating expectations. The chart below visualizes how TOI has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

TOI has released its 2025 Q4 earnings report, with revenue of 141.96M, reflecting a YoY change of 41.58%, and net profit of -7.51M, showing a YoY change of 43.04%. The Sankey diagram below clearly presents TOI's revenue sources and cost distribution.